Phase III BMT CTN 0702 Stamina Trial Results

Phase III BMT CTN 0702 Stamina Trial Results

ASHReport

3 years
1,055 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Parameswaran Hari, MD, MRCP, MS of Medical College of Wisconsin gives an overview of the results and aftermath of Phase III BMT CTN 0702 Stamina Trial at the 58th ASH Annual Meeting in San Diego, CA.
Up Next Autoplay
ArcherDX Personalized Cancer Monitoring (PCM) Technology Designated by FDA as Breakthrough Device
ArcherDX Personalized Cancer Monitoring (PCM) Technology Designated by FDA as Breakthrough Device
Category: News
0 Views
Cancer-News 1 day
Pacific Brain Tumor Center Recruiting Patients with Rare Cancer of the Skull and Spine for Groundbreaking Clinical Trial
Pacific Brain Tumor Center Recruiting Patients with Rare Cancer of the Skull and Spine for Groundbreaking Clinical Trial
Category: Brain Cancer
3 Views
Cancer-News 2 days
Molecular AI Product: What's Next For Research?
Molecular AI Product: What's Next For Research?
Category: News
10 Views
Cancer-News 1 week
Molecular AI Product: Can It Be Used Now or Later?
Molecular AI Product: Can It Be Used Now or Later?
Category: News
9 Views
Cancer-News 1 week
Caris Life Sciences Launches First Ever Molecular AI Product
Caris Life Sciences Launches First Ever Molecular AI Product
Category: News
24 Views
Cancer-News 1 week
Acepodia Announces FDA Clearance of IND for its NK Cell Therapy Drug Candidate ACE1702 to Treat Patients with HER2-expressing Solid Tumors
Acepodia Announces FDA Clearance of IND for its NK Cell Therapy Drug Candidate ACE1702 to Treat Patients with HER2-expressing Solid Tumors
Category: Other
19 Views
Cancer-News 1 week
Caris Life Sciences Launches First Ever Molecular AI Product: A Clinical Genomic Profiling Similarity Score
Caris Life Sciences Launches First Ever Molecular AI Product: A Clinical Genomic Profiling Similarity Score
Category: News
8 Views
Cancer-News 1 week
Verastem Oncology Announces Global Licensing Agreement with Chugai Pharmaceutical Co., Ltd. to Develop and Commercialize RAF/MEK Inhibitor CH5126766
Verastem Oncology Announces Global Licensing Agreement with Chugai Pharmaceutical Co., Ltd. to Develop and Commercialize RAF/MEK Inhibitor CH5126766
Category: News
6 Views
Cancer-News 1 week
New Study Finds Blood Clots More Likely in Children Who Receive Peripherally Inserted Central Catheters
New Study Finds Blood Clots More Likely in Children Who Receive Peripherally Inserted Central Catheters
Category: News
2 Views
Cancer-News 1 week
Role of Radiation in Kidney Cancer
Role of Radiation in Kidney Cancer
Category: Kidney Cancer
5 Views
kidneycancer 1 week